No connection

Search Results

ABBV vs CCEL

ABBV
AbbVie Inc.
NEUTRAL
Price
$219.26
Market Cap
$387.52B
Sector
Healthcare
AI Confidence
68%
CCEL
Cryo-Cell International, Inc.
BEARISH
Price
$3.67
Market Cap
$29.6M
Sector
Healthcare
AI Confidence
95%

Valuation

P/E Ratio
ABBV
163.63
CCEL
--
Forward P/E
ABBV
15.42
CCEL
183.5
P/B Ratio
ABBV
-146.66
CCEL
-1.61
P/S Ratio
ABBV
6.5
CCEL
0.95
EV/EBITDA
ABBV
15.27
CCEL
31.86

Profitability

Gross Margin
ABBV
71.46%
CCEL
63.53%
Operating Margin
ABBV
35.5%
CCEL
9.96%
Profit Margin
ABBV
4.0%
CCEL
-8.52%
ROE
ABBV
137.96%
CCEL
--
ROA
ABBV
9.59%
CCEL
0.19%

Growth

Revenue Growth
ABBV
9.1%
CCEL
-3.6%
Earnings Growth
ABBV
-88.7%
CCEL
-80.5%

Financial Health

Debt/Equity
ABBV
--
CCEL
--
Current Ratio
ABBV
0.72
CCEL
0.62
Quick Ratio
ABBV
0.47
CCEL
0.55

Dividends

Dividend Yield
ABBV
3.05%
CCEL
16.35%
Payout Ratio
ABBV
490.15%
CCEL
3962.91%

AI Verdict

ABBV NEUTRAL

The Advanced Deterministic Scorecard reveals a mixed health profile with a Piotroski F-Score of 4/9 indicating stable but not strong fundamentals, while the absence of an Altman Z-Score prevents a clear distress risk assessment. Despite robust operating margins and consistent revenue growth, the company faces significant headwinds from negative earnings growth, an extremely high P/E ratio, and a dangerously elevated payout ratio. Strong historical price performance and analyst buy sentiment are counterbalanced by bearish insider activity and deteriorating profitability trends. The stock appears to trade at a substantial premium to its intrinsic value, suggesting limited margin of safety.

Strengths
High operating margin (35.50%) indicating strong pricing power and cost control
Consistent revenue growth (9.10% YoY) outpacing sector average
Strong track record of earnings surprises (22 out of 25 quarters beat estimates)
Risks
Extremely high P/E ratio (163.63) vs forward P/E (15.42), suggesting potential overvaluation on trailing basis
Earnings growth collapsing (YoY: -88.70%, Q/Q: -88.10%) indicating severe profitability deterioration
Unsustainable dividend payout ratio (490.15%) threatening dividend security
CCEL BEARISH

CCEL exhibits severe financial distress, highlighted by a weak Piotroski F-Score of 2/9 and a negative Price/Book ratio of -1.61, suggesting negative shareholder equity. The company's dividend is fundamentally unsustainable with a payout ratio of 3962.91%, indicating that dividends are being paid out of capital or debt rather than earnings. While gross margins remain strong, the combination of declining YoY revenue (-3.60%) and crashing earnings growth (-80.50%) creates a precarious outlook. Liquidity is a critical concern with a current ratio of 0.62, placing the firm at significant short-term financial risk.

Strengths
Strong gross margins at 63.53%
Positive operating margin of 9.96%
Low Price/Sales ratio of 0.95
Risks
Negative equity as indicated by Price/Book ratio of -1.61
Severe liquidity risk with a current ratio of 0.62 and quick ratio of 0.55
Unsustainable dividend payout ratio (3962.91%)

Compare Another Pair

ABBV vs CCEL: Head-to-Head Comparison

This page compares AbbVie Inc. (ABBV) and Cryo-Cell International, Inc. (CCEL) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI Chat
Markets
Profile